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Infections due Scedosporium spp. in lung transplant recipients are associated with disseminated disease
with high mortality rates. The adjunctive local antifungal therapy may be a useful option when systemic
treatment is insufﬁcient and/or surgery is not feasible. We present a case of mixed disseminated infection
due Scedosporium apiospermum and S. proliﬁcans in a lung transplant recipient. Combined local and
systemic antifungal therapy provided an unusual long-term survival in the intensive care unit.
& 2016 The Authors. International Society for Human and Animal Mycology. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Scedosporium species are opportunistic fungal pathogens re-
cognized as a cause of infection in patients with solid organ transplant
(SOT). In lung transplant (LT) recipients the invasive pulmonary in-
fection and disseminated disease are the predominant manifestations
and carry high mortality rates [1]. Voriconazole (VRC) is re-
commended as ﬁrst line of therapy for Scedosporium spp. infections
however, treatment options are often limited due to resistance/less
susceptibility to current antifungal drugs [2]. Several antifungal com-
binations have been employed but nowadays, no solid recomme-
ndations have been made, remaining still a concern.
We present a case of mixed disseminated infection due S. apios-
permum and S. proliﬁcans in a LT recipient. He was treated with a very
broad combination of systemic and local antifungal agents achieving
an outstanding prolonged survival in the Intensive Care Unit (ICU).for Human and Animal Mycology.
d/4.0/).2. Case
A 27-years-old man with cystic ﬁbrosis (CF) underwent bilateral
lung transplant on May 2014 (day 0). He was chronically colonizated
with S. apiospermum and received long-term suppressive therapy with
VRC. Anti-infective prophylaxis included broad-spectrum antibiotics,
intravenous VRC 200 mg twice daily, intravenous liposomal ampho-
tericin B (L-AMB) 350mg daily and nebulized L-AMB 25 mg (L-AMB
50 mg diluted in 12 cc of sterile water and remove 6 cc from the
mixture) daily. Maintenance immunosuppressive therapy consisted in
tacrolimus and prednisone. His immediate post-transplant course was
complicated by an urgent surgery for massive left hemothorax. On
day þ7, the patient developed multifactorial acute kidney injury and
renal replacement therapy (RRT) was started.
On day þ30, he required surgical intervention for left pleural
empyema. Cultures from respiratory tract samples and pleural ﬂuid
revealed S. proliﬁcans and S. apiospermum. The antimycotic treatment
was intensiﬁed; intravenous VRC was associated with terbinaﬁne
(TRB) 250 mg daily, caspofungin (CAS) 50 mg daily, nebulized VRCPublished by Elsevier B.V. This is an open access article under the CC BY-NC-ND
Fig. 1. Axial image from contrast-enhanced computed tomography scan of the chest showing a ﬁlling defect compatible with thrombus in the anastomosis of right pul-
monary artery (arrows). The diameter of lesions shown are (a) 1710 mm and (b) 118 mm observed after intensive antifungal therapy.
Fig. 2. Histopathology demonstrating organized hematic material that includes
fungal organism with narrow-angle branching septate hyphae (periodic – acid
Schiff [PAS] stain X 400).
Table 1
Results of individual and combined antifungal activity in S. apiospermum and S.
proliﬁcans isolates sent to the Mycology Reference Laboratory.
Organism MIC a FIC b
VRC POS CAS TRB MTF VRC–MTF POS–MTF
Scedosporium
apiospermum
0.12 r12 NT NT 0.12 2 2
Scedosporium
proliﬁcans
416 416 4 416 16 2 2.5
Abbreviations: MIC minimal inhibitory concentration (mg/L), FIC fractional in-
hibitory concentration index, VOR voriconazole, POS posaconazole, CAS caspo-
fungin, TRB terbinaﬁne MTF miltefosine, NT not tested.
a Individual MICs were determined following the broth microdilution method
recommended by EUCAST.
b MIC of VOR and POS in combination with MTF was performed by using a two-
dimensional checkerboard microdilution method. The ﬁnal concentration assayed
ranged from 16 to 0.12 mg/L for VOR, 16–0.12 mg/L for POS and 32–0.06 mg/L for
MTF. The interaction between drugs was quantitatively evaluated by means of the
FIC. The interaction was deﬁned as synergistic if the FIC index was 0.5, additive if
FIC was 40.5 ando1, indifferent if 1oFIC 44, and antagonistic if FIC was 44.
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from the mixture) three times daily and intrapleural instillations with
VRC (400 mg in 100ml of normal saline) twice daily. Intravenous
L-AMB was discontinued. Serum VRC levels were monitored twice
monthly resulting in subtherapeutic levels (o1 mg/L) in all samples
but antifungals dose was not increased due to a progressive increase
in liver enzyme levels and renal failure. The patient recovered clini-
cally and maintained an acceptable lung function with minimal oxy-
gen requirements. He was discharged to general ward on day þ87.
However, on day þ90 the patient was readmitted to ICU due severe
respiratory failure requiring continuous mechanical ventilation. A
bronchoscopy was performed and cultures from bronchoalveolar la-
vages and pleural ﬂuid remained positive for S. proliﬁcans and S.
apiospermum. A chest computed tomography (CT) evidenced a
thrombus in the anastomosis of right pulmonary artery and bibasilar
pulmonary consolidations (Fig. 1a). Thrombus sample was taken
through an intravascular catheter with embolic protection device.
Histopathological evaluation revealed organized hematic material
with visible fungal elements (Fig. 2).
The patient received a new combination of antifungal therapy
with intravenous posaconazole (POS) 300 mg once daily, miltefo-
sine (MTF) 50 mg twice daily and anidulafungin (ANF) 100 mg
daily. Intrapleural VRC, nebulized VRC and nebulized L-AMB were
maintained. Intravenous VRC, TRB and CAS were discontinued.
Surgery was ruled out due to progressive disseminated infection.
Fungal strains isolated from respiratory, pleural ﬂuid and
thrombus samples were sent to the Mycology Reference Labora-
tory to be conﬁrmed. Deﬁnitive identiﬁcation was performed by
macro-microscopic morphological characteristics and by real time
PCR assay speciﬁc for the detection of S. apiospermum and S. pro-
liﬁcans [3]. Antifungal activity of VRC, POS, CAS and MTF weretested and a synergy test was also performed by checkerboard-
microdilution method [4]. S. apiospermum was susceptible to VRC,
POS and MTF, while S. proliﬁcans was resistant to all antifungals
tested. In addition, neither synergy between VRC–MTF nor POS–
MTF was present (Table 1) [5].
Progressive improvement was observed, and on day þ160 a
reduction of the thrombus size was seen in a control chest CT
(Fig. 1b). Cultures from respiratory tract and pleural ﬂuid samples
became negative consequently, intrapleural VRC was discontinued
and POS switched to oral therapy (200 mg four times daily). POS
concentration was also monitored twice monthly with levels
ranged between 0.31 and 1.17 mg/L. Nevertheless, the patient re-
mained in ICU due to critical illness polyneuropathy with difﬁcult
weaning from mechanical ventilation.
On day þ230 the patient started with new-onset dyspnea and
fever. A new chest CT revealed a big mass in the tricuspid valve, an
increase in the size of the thrombus of the right pulmonary artery
with distal progression, and a new thrombus in the anastomosis of
left pulmonary artery, suggesting mycotic emboli (Fig. 3). Trans-
thoracic echocardiography conﬁrmed a large vegetation on tri-
cuspid valve (Fig. 4).
S. proliﬁcans and S. apiospermum were identiﬁed on respiratory
samples and the patient died on day þ245 due multiorgan failure.3. Discussion
Scedosporium spp. accounts for to 25% of all non-Aspergillus
mold infections in SOT [6], being the second most frequently ﬁ-
lamentous fungi recovered in patient with LT [7]. Disseminated
Fig. 3. Axial image from contrast-enhanced computed tomography scan of the chest showing a ﬁlling defect compatible with thrombus (arrows). The size of lesions shown
are (a) 710 mm in right pulmonary artery and (b) 145 mm in the anastomosis of left pulmonary artery.
Fig. 4. Transthoracic echocardiography of right heart structures showing tricuspid
valve with a large vegetation (3618 mm) suggestive fungal endocarditis.
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porium spp. infection, and it usually carries an ominous prognosis,
with mortality rates around 80% [6–8].
Time to onset Scedosporium spp. disease varies greatly, from
ﬁrst month after transplant to several years later. Increased mor-
tality with early-onset infection is expected during the pre-en-
graftment period, and most patients die during the ﬁrst month
following the diagnosis [7,8]. Scedosporium spp. disseminated in-
fections with intravascular involvement is usually a fulminant
process in an immunocompromised patient [7,9]. We present a LT
patient with an early-onset Scedosporium spp. disseminated dis-
ease with lung, intravascular and endocardial involvement. Re-
gardless the poor prognosis, the patient presented an ex-
ceptionally long-term survival in ICU, nearly 9 months, probably
attributed to a broad antifungal combination therapy.
The genus Scedosporium show decreased susceptibility to the
majority of current antifungal agents. VRC is recommended as
ﬁrst-line treatment for Scedosporium spp. infections. S. apios-
permum demonstrates variable susceptibility to azoles and echi-
nocandins. S. proliﬁcans is generally resistant to most antifungal
drugs [2]. The usefulness of combination therapy for Scedosporium
spp. infections is controversial and in most cases applied as sal-
vage therapy. Several in vitro studies have demonstrated successful
growth inhibition of Scedosporium spp. when combining anti-
fungals [10,11]. Several cases reported successful treatment with
azole plus terbinaﬁne or azole plus echinocandins, nevertheless
these combinations are moderately or marginally recommended
respectively, for the treatment of Scedosporium spp. infections [2].
The experience of MTF combined in Scedosporium spp. infections isanecdotal, and only one case report with successful outcome is
available [12].
We started an intensive systemic therapy with VRC, TRB and
CAS combined with intrapleural and nebulized VRC obtaining a
transient clinical improvement. An increase in liver enzymes at-
tributed to the antifungal therapy occurred and he was kept on
RRT during all ICU admission. These inconveniences compelled us
to a change systemic therapy to POS, MTF and ANF. At that time,
our patient was in a critical condition, and oral intake was de-
creased. The new intravenous formulation of POS provides an
option for the same indications in patients who are inable to re-
ceive oral formulations [13]. A case report has shown that in-
travenous POS may be used in critically ill patient undergoing RRT
without signiﬁcant risk of cyclodextrin accumulation [14]. We
started with intravenous POS with the aim of achieving a through
concentration at least Z1 mg/L as literature recommended [15]. A
signiﬁcant clinical improvement was observed, with a reduction in
the size of thrombus, and negative cultures were obtained in re-
spiratory samples.
In our patient, therapeutic levels of VRC never were achieved
and POS levels varied greatly. Data from real world studies in CF
patients indicate a high inter-subject variability in azole pharma-
cokinetics, achieving appropriate levels can be challenging in
these patients [16].
The susceptibility patterns of Scedosporium spp. to current an-
tifungal agents is difﬁcult to predict and synergy tests may be
useful to choose the more appropriate treatment [10]. The
checkerboard test provides a two-dimensional arrangement of
different concentrations of antimicrobials and allows the calcula-
tion of the fractional inhibitory concentration index (FIC), asses-
sing the additivity, indifference or antagonism between anti-
microbials [4]. Unfortunately, the results obtained in our patient
samples showed that S. apiospermum was susceptible to VRC, POS
and MTF, while S. proliﬁcans was resistant to all antifungal agents
used. Besides, each antifungal combination showed indifference
interaction for both strains.
Systemic antifungal therapy in Scedosporium spp. infection is
not always effective. Surgical removal of the affected tissue has
been a component of the standard of care and should be con-
sidered whenever possible [2,7]. Surgery was ruled out in our
patient due to critical situation and disseminated infection. On this
issue, local (nebulized plus intrapleural) antifungals may provide
higher concentrations at the site of infection without increasing
the risk of systemic side-effects and may be a promising option to
not-candidate patients. Some studies reports successful treat-
ments in invasive pulmonary aspergillosis and Aspergillus pleural
empyema with local antifungal therapy [17,18] and at present time
only one case describes successful treatment with nebulized VRC
in S. apiospermum pulmonary infection in CF patient, highlighting
the therapeutic potential and the safety of these alternative
B. Balandin et al. / Medical Mycology Case Reports 11 (2016) 53–5656administration routes [19].
Despite the hopelessness of the case, we assume that the pa-
tient could have a realistic chance of survival. Therefore, treatment
was aimed to suppress the progression of the infection and open
the possibility of a surgical approach.
We report an early onset disseminated infection due S. apios-
permum and S. proliﬁcans in a CF patient with LT. The patient
survived nearly 9 months in ICU, an unusually survival time much
greater than described in the literature. In addition, this is the ﬁrst
report describing a combination of systemic, intrapleural and
nebulized antifungal therapy in Scedosporium spp. mixed dis-
seminated infection in LT recipient.
We must acknowledge some limitations as antifungals agents
failed to show in vitro synergy and besides, we could not de-
termine the most effective antifungal drug used. Nevertheless, we
assume that the antifugals combination described here was ef-
fective in slowing the progression of the disease and prolonging
the patient's survival.
The relevance of this report is highlighted by the fact that a
very broad combination of systemic and local antifungals in Sce-
dosporium spp. invasive infections as described may be an option
in severely ill patients with surgical chance awaiting deﬁnitive
treatment.Conﬂict of interest
There are none.Acknowledgments
MA. Romera, B. Lobo and P. Galdos for reviewing the
manuscript.References
[1] A. Bhaskaran, S.M. Hosseini-Moghaddam, C. Rotstein, S. Husain, Molds infec-
tions in lung transplant recipients, Semin. Respir. Crit. Care Med. 34 (2013)
371–379.
[2] A.M. Tortorano, M. Richardson, E. Roilides, A. van Diepeningen, M. Caira,
P. Muñoz, et al., ESCMID and ECMM joint guidelines on diagnosis andmanagement of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and
others, Clin. Microbiol. Infect. 20 (2014) 27–46.
[3] M.V. Castelli, M.J. Buitrago, L. Bernal-Martínez, A. Gómez-López, J.L. Rodriguez-
Tudela, M. Cuenca-Estrella, Development and validation of a quantitative PCR
assay for diagnosis of scedosporiosis, J. Clin. Microbiol. 46 (2008) 3412–3416.
[4] F.C. Odds, Synergy, antagonism, and what the chequerboard puts between
them, J. Antimicrob. Chemother. 52 (2003) 1.
[5] EUCAST deﬁnitive document E.DEF 9.1: EUCAST Technical Note on the method
for the determination of broth dilution minimum inhibitory concentration of
antifungal agents for conidia-forming moulds. Clin Microbiol Infect, vol. 14,
2008, pp. 982–984.
[6] A. Solé, M. Salavert, Fungal infections after lung transplantation, Curr. Opin.
Pulm. Med. 15 (2009) 243–253.
[7] K.J. Cortez, E. Roilides, F. Quiroz–Tellez, J. Meletiadis, C. Antachopoulos,
T. Knudsen, et al., Infections caused by Scedosporium spp, Clin. Microbiol. Rev.
21 (2008) 157–197.
[8] L.S. Johnson, R.K. Shields, C.J. Clancy, Epidemiology, clinical manifestations,
and outcomes of Scedosporium infections among solid organ transplant re-
cipients, Transpl. Infect. Dis. 16 (2013) 578–587.
[9] M.L. Fernández-Guerrero, E. Askari, E. Prieto, I. Gadea, A. Román, Emerging
infectious endocarditis due to Scedosporium proliﬁcans: a model of therapeutic
complexity, Eur. J. Clin. Microbiol. Infect. Dis. 30 (2011) 1321–1324.
[10] R. Araujo, M. Oliveira, A. Amorim, B. Sampaio-Maia, Unpredictable suscept-
ibility of emerging clinical moulds to tri-azoles: review of the literature and
upcoming challenges for mould identiﬁcation, Eur. J. Clin. Microbiol. Infect.
Dis. 34 (2015) 1289–1301.
[11] C. Biswas, T.C. Sorrell, J.T. Djordjevic, X. Zuo, K.A. Jolliffe, S.C. Chen, In vitro
activity of miltefosine as a single agent and in combination with voriconazole
or posaconazole against uncommon ﬁlamentous fungal pathogens, J. Anti-
microb. Chemother. 68 (2013) 2842–2846.
[12] A.M. Kesson, M.C. Bellemore, T.J. O´Mara, D.H. Ellis, T.C. Sorrell, Scedosporium
proliﬁcans osteomyelitis in an immunocompetent child treated with a novel
agent, hexadecylphospocholine (miltefosine), in combination with terbinaﬁne
and voriconazole: a case report, Clin. Infect. Dis. 48 (2009) 1257–1261.
[13] McKeage, K. Posaconazole, A review of the gastro-resistant tablet and in-
travenous solution in invasive fungal infections, Drugs 75 (2015) 397–406.
[14] A.A. Morris, S.W. Mueller, J.E. Rower, T. Washburn, T.H. Kiser, Evaluation of
sulfobutylether-β-cyclodextrin in exposure in a critically ill patient receiving
intravenous posaconazole while undergoing continuous venovenous hemo-
ﬁltration, Antimicrob. Agents Chemother. 59 (2015) 6653–6656.
[15] H.R. Ashbee, R.A. Barnes, E.M. Johnson, M.D. Richardson, R. Gorton, W.
W. Hope, Therapeutic drug monitoring (TDM) of antifungal agents: guidelines
from the British Society for Medical Mycology, J. Antimicrob Chemother. 69
(2014) 1162–1176.
[16] F.M. C Müller, M. Seidler, Characteristic of pathogenic fungi and antifungal
therapy in cystic ﬁbrosis, Expert Rev. Anti-Infect. Ther. 69 (2010) 957–964.
[17] S.C. Ko, K.Y. Chen, P.R. Hsueh, K.T. Luh, P.C. Yang, Fungal empyema thoracis. An
emerging clinical entity, Chest 117 (2000) 1672–1678.
[18] O. Hilberg, C.U. Andersen, O. Henning, T. Lundy, J. Mortensen, Bendstrup, Re-
markably efﬁcient inhaled antifungal monotherapy for invasive pulmonary
aspergillosis, Eur. Respire. J. 40 (2012) 271–273.
[19] J. Holle, M. Leichsenring, P.E. Meissner, Nebulized voriconazole in infections
with Scedosporium apiospermum – case report and review of literature, J. Cyst.
Fibros. 13 (2014) 400–402.
